Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alphamab Oncology ( (HK:9966) ) has issued an update.
Alphamab Oncology announced that phase III trial results for KN026, its anti-HER2 bispecific antibody co-developed with CSPC subsidiary JMT-Bio, in combination with albumin-bound docetaxel HB1801 as neoadjuvant therapy for HER2-positive breast cancer, have been selected for a Late-Breaking Abstract oral presentation at the 2026 ASCO Annual Meeting. The head-to-head study showed KN026 plus HB1801 significantly improved total pathological complete response versus the current standard regimen of trastuzumab, pertuzumab and docetaxel, suggesting the regimen could become a new standard of care and reinforcing Alphamab’s position in HER2-targeted oncology, while KN026 continues to advance through multiple registrational trials in breast and gastric cancers with regulatory designations in China and the U.S.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$9.60 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a China-based biopharmaceutical company focused on developing innovative oncology therapies, including bispecific antibodies such as KN026. The company targets cancers driven by HER2 and other biomarkers, with a growing portfolio of late-stage clinical programs and partnerships that emphasize both domestic and international commercialization opportunities.
Average Trading Volume: 1,559,211
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$10.94B
Find detailed analytics on 9966 stock on TipRanks’ Stock Analysis page.